Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Hodgkin Disease

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Hodgkin Lymphoma

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Bleomycin

Vinblastine

Doxorubicin

Liposomal doxorubicin

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Tubulin Modulators

Antimitotic Agents

Adriamycin

DTIC

30 Gy IF-RT

20 Gy IF-RT

Volker Diehl, Prof.

This study is designed to find the optimum radiation dose and number of cycles for an ABVD chemotherapy combined with an involved field irradiation. It is to be tested whether the reduction from 4 to 2 cycles of ABVD and/or the reduction of the radiation dose from 30 to 20 Gy is feasible without a loss of efficacy.

HD10 for Early Stages

University of Cologne

Antirheumatic Agents

Anti-Inflammatory Agents

Hematinics

Cyclophosphamide

Prednisone

Vincristine

Epoetin Alfa

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Adramycin

Procarbacine

Erythropoietin beta

Andreas Josting, Dr.

This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

Etoposide

Etoposide phosphate

Procarbazine

radiation therapy

This study is designed to test (1) whether the BEACOPP dosage can be reduced to baseline in the last 4 cycles without loss of effectiveness, and (2) whether consolidating irradiation is necessary following effective chemotherapy.

HD12 for Advanced Stages

This study is designed to (1) compare the efficacy of the BEACOPP regimen with that of ABVD as a 4-cycle chemotherapy combined with an involved field irradiation and (2) to define the optimum radiation dose comparing of 30 to 20 Gy in the same context.

HD11 for Intermediate Stages

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
HD10 for Early Stages	NCT00265018	Hodgkin´s Lymph...	Adriamycin Bleomycin Vinblastine DTIC 30 Gy IF-RT 20 Gy IF-RT	16 Years - 75 Years	University of Cologne
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma	NCT00284271	Hodgkin´s Lymph...	Cyclophosphamid... Adramycin Procarbacine Prednisone Vincristine Bleomycin Erythropoietin ...	61 Years - 75 Years	University of Cologne
HD12 for Advanced Stages	NCT00265031	Hodgkin´s Lymph...	Cyclophosphamid... Adriamycin Etoposide Procarbazine Prednisone Vincristine Bleomycin radiation thera...	16 Years - 65 Years	University of Cologne
Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma	NCT00284271	Hodgkin´s Lymph...	Cyclophosphamid... Adramycin Procarbacine Prednisone Vincristine Bleomycin Erythropoietin ...	61 Years - 75 Years	University of Cologne
HD11 for Intermediate Stages	NCT00264953	Hodgkin´s Lymph...	Adriamycin Bleomycin Vinblastine DTIC Etoposide Procarbazine Prednisone Vincristine radiation thera...	16 Years - 75 Years	University of Cologne

Spots Global Cancer Trial Database for hodgkin´s lymphoma